News Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Delayed OTC Markets Other stock markets 09:30:02 2024-04-25 am EDT			5-day change	1st Jan Change
0.55 ^USD	+1.85%		-3.51%	-17.54%

Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	Apr. 03	CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	Mar. 26	AQ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	Feb. 20	AQ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	Feb. 20	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06	MT
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	Feb. 06	AQ
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	Feb. 05	CI
North American Morning Briefing : Stock Futures -2-	Nov. 27	DJ
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Summary

Filters